“In taking Amgen but not Bristol, the court may have wanted to wade into this complex area one toe at a time,” one expert said. […]
Elon Musk’s Neuralink has been the buzz of Silicon Valley and beyond. But it’s hardly the only company developing “brain-computer interfaces.” […]
In some of his first public remarks since getting booed on stage last month over Alzheimer’s drug remarks, Regeneron’s George Yancopoulos acknowledged in an interview he could’ve handled things differently. […]
Copyright © 2023 Biotech Networks, LLC
